Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3133-3137

  Oude Lashof, A M L ^a,b   Sobel, J D ^c   Ruhnke, M ^d   Pappas, P G ^e   Viscoli, C ^f   Schlamm, H T ^g   Rex, J H ^h   Kullberg, B J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF GENOA   (Italy)

^g Pf Izer Global Research and Development   (United States)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; FLUCONAZOLE; VORICONAZOLE;

ADULT; AGED; ANURIA; ARTICLE; CANDIDEMIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INFUSION RELATED REACTION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OLIGURIA; PRIORITY JOURNAL; SEPTIC SHOCK; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TRIAZOLES; YOUNG ADULT;

EID: 84861165091     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05841-11     Document Type: Article

References (12)

1. Abel S, et al. 2008. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin. Drug Invest. 28:409-420. (Pubitemid 351821478)
2. Alvarez-Lerma F, et al. 2008. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J. Chemother. 20:93-100. (Pubitemid 351428669)
3. Burkhardt O, Thon S, Burhenne J, Welte T, Kielstein JT. 2010. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. Int. J. Antimicrob. Agents 36:93-94.
4. Hafner V, et al. 2010. Pharmacokinetics of sulfobutylether-beta- cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob. Agents Chemother. 54:2596-2602.
5. Herbrecht R, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415. (Pubitemid 34851833)
6. Kullberg BJ, et al. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435-1442. (Pubitemid 41483809)
7. Luke DR, Tomaszewski K, Damle B, Schlamm HT. 2010. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J. Pharm. Sci. 99:3291-3301.
8. Pfaller MA, et al. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39:3254-3259. (Pubitemid 32830323)
9. Saliba F, Dupont B. 2008. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med. Mycol. 46:97-112. (Pubitemid 351372328)
10. von Mach MA, Burhenne J, Weilemann LS. 2006. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. B.M.C. Clin. Pharmacol. 6:6.
11. Walsh TJ, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360. (Pubitemid 351265310)
12. Walsh TJ, et al. 2000. New targets and delivery systems for antifungal therapy. Med. Mycol. 38(Suppl. 1):335-347. (Pubitemid 32094081)